×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

 

Jackson Egen

Director
Oncology Research

Since joining Amgen in 2015, Jackson has led a research group focused on identifying basic mechanisms of immune evasion by solid tumors, with the goal of translating these findings to the development of novel therapeutics for cancer and immune-mediated diseases. The group’s specific areas of interest include deciphering mechanisms by which heterogenous populations of tumor-associated myeloid and stromal cells regulate adaptive immune responses and identifying novel regulators of antigen presenting cell function in the context of T cell-mediated inflammation and anti-tumor immunity.

Prior to joining Amgen, Jackson led a group in the Department of Immunology at Genentech investigating the pathogenesis of autoimmune and fibrotic diseases. He received his PhD from the University of California at Berkeley in the laboratory of James P. Allison studying the mechanisms by which CTLA-4 and CD28 regulate T cell responses and was a post-doctoral fellow and staff scientist at the National Institutes of Health in the laboratory of Ronald N. Germain where he investigated the regulation of immune cell migration under conditions of tissue inflammation.

Featured Publications

Zhang L, Li Z, Skrzypczynska KM, Fang Q, Zhang W, O’Brien SA, He Y, Wang L, Zhang Q, Kim A, Gao R, Orf J, Wang T, Sawant D, Kang J, Bhatt D, Lu D, Li CM, Rapaport A, Perez K, Ye Y, Wang S, Hu X, Ren X, Ouyang W, Shen Z*, Egen JG*, Zhang Z*, Yu X*. Combined Single-Cell Analyses Reveal Distinct Mechanisms of Myeloid-Targeted Immunotherapies. Cell. 2020 Apr 16;181(2):442-459 *Co-corresponding authors http://pubmed.gov/32302573

Egen JG, Ouyang W, Wu LC. Human Anti-tumor Immunity: Insights from Immunotherapy Clinical Trials. Immunity. 2020 Jan 14;52(1):36-54 http://pubmed.gov/31940272

Tarbell KV*, Egen JG*. Breaking self-tolerance during autoimmunity and cancer immunity: Myeloid cells and type I IFN response regulation. J Leukoc Biol. 2018 Feb 2; 103:1117–1129 *Co-corresponding authors http://pued.gov/29393979

Lamb CA, Mansfield JC, Tew W, Gibbons D, Long AK, Irving P, Diehl L, Eastham-Anderson J, Price M, O’Boyle G, Jones DEJ, O’Byrne S, Hayday A, Keir M*, Egen JG*, Kirby JA*. αEβ7 Integrin Identifies Subsets of Pro-Inflammatory Colonic CD4+ T Lymphocytes in Ulcerative Colitis. J Crohns Colitis. 2017 May 1;11(5):610-620 *Co-corresponding authors http://pubmed.gov/28453768

Education

Postdoctoral Fellowship, National Institutes of Health
Ph.D., Immunology, University of California- Berkeley
B.S., Biochemistry, University of Arizona